News by Wire Article
December 10, 2025 | Time: | Location: | Category: News
Committed to Making a Difference: Kumar Brings Experience and Expertise to Drive Advances in Clinical Research Worldwide
A renowned pharmaceutical entrepreneur and philanthropist who has actively driven advances in clinical research and ensuring quality healthcare is accessible to all has started a new advisory role with US-based oncology research organisation START.
Kumar Muthalagappan OBE will assist the pre-eminent phase one oncology research organisation South Texas Accelerated Research Therapeutics (START) in its quest to expand globally – particularly into Europe and other markets.
With 10 existing sites globally – principally in America as well as Dublin, Barcelona, Rioja, Madrid and Lisbon – START’s key aim is to accelerate the development of anti-cancer drugs, helping to improve the quality of life and survival rates for patients with cancer and to lead to its eventual cure.
His new role follows another new appointment earlier this year as Strategic Advisor and Catalyst Council Member of CRIO – an e-Source solution which collects patient data for the purpose of clinical research trials.
Kumar brings a wealth of experience to his new roles. In 2009 he was called upon to give strategic advice to MeDiNova – a small clinical research company undertaking clinical trials for a range of conditions such as asthma, COPD and osteoporosis with the principal aim of bringing novel treatments to patients.
Kumar Muthalagappan OBE will assist the pre-eminent phase one oncology research organisation South Texas Accelerated Research Therapeutics (START) in its quest to expand globally – particularly into Europe and other markets.
With 10 existing sites globally – principally in America as well as Dublin, Barcelona, Rioja, Madrid and Lisbon – START’s key aim is to accelerate the development of anti-cancer drugs, helping to improve the quality of life and survival rates for patients with cancer and to lead to its eventual cure.
His new role follows another new appointment earlier this year as Strategic Advisor and Catalyst Council Member of CRIO – an e-Source solution which collects patient data for the purpose of clinical research trials.
Kumar brings a wealth of experience to his new roles. In 2009 he was called upon to give strategic advice to MeDiNova – a small clinical research company undertaking clinical trials for a range of conditions such as asthma, COPD and osteoporosis with the principal aim of bringing novel treatments to patients.
Kumar later took the helm as company CEO and Chairman, growing turnover from £500,000 to £40 million and growing MeDiNova to 106 sites in eight different countries, resulting in providing treatment opportunities to thousands of patients in varying communities.
He later established global cancer clinical research company Oncacare – bringing patients, oncologists and pharmaceutical organisations together and driving global oncology developments, aiding the successful treatment of cancer and bringing fresh hope to millions of cancer patients worldwide.
Other more recent additions to his impressive career portfolio include his appointment as Senior Independent Director of Tennessee-based Objective Health, which works towards making clinical trials accessible to patients within their communities, and Senior Strategic Advisor to investment firm Vitruvian Partners, lending his expertise within the Healthcare and Life Sciences Projects sector.
Kumar said: “I am delighted to be given the opportunity to bring my experience and expertise to START as it seeks to extend its reach into more countries, benefiting thousands more people across the world.
“START, CRIO Objective Health and Vitruvian Partners are all highly innovative and ambitious companies each with the common goal of improving healthcare and patient accessibility to world-class treatment and it is an honour to work with such companies which are at the forefront of developing new treatments for unmet medical conditions.”
Kumar’s appointments come as Professor Antoine Italiano Head of Department of Medicine at Institut Bergonié in Bordeaux, Head of Precision Medicine at Gustave Roussy, Paris paid tribute to him for his expertise.
Writing on his LinkedIn profile he said: “I met Kumar five years ago when he founded Oncacare.
“From the very beginning I was impressed not only by his entrepreneurial vision but also by his kindness, generosity and ability to bring people together around important causes.
“Seeing his journey – from building successful ventures to now dedicating so much energy to healthcare and philanthropy – has been truly inspiring. Kumar embodies what it means to combine business leadership with a deep sense of purpose.”
Press release date: December 9, 2025 - https://newsbywire.com/
